Agenus’ Post

Patent Expirations: Large bio/pharmaceutical companies are facing a significant revenue threat due to the upcoming biologics patent cliff, which could jeopardize an estimated $300 billion–$350 billion in revenue over the next three years. FinBio estimates that between 2023 and 2030 over 5,000 drug patents will expire, with Oncology products representing ~20% of the total. Leading Products w/Patent Expiry by Revenues: #1 KEYTRUDA® (pembrolizumab) HCP Merck #2 Buy Eliquis 5mg online US to US Delivery 7*24Bristol Myers Squibb Elizabeth Rosario One major pressing question remains: Will Keytruda be able to successfully extend its patent expiry date from 2028?

Trying to determine comparatiive value in settings such as oncology, where drug markups drive overall cost of care, causes a divide by zero error. This is because in ths case you are comparing cost/benefit between different alternatives. Because the benefit to the patient, provider, or pharmaceutical company is zero....the system crashes.

Ever wondered how to navigate the complex landscape of advisors, consultants, collaborators, and partners in the pharmaceutical industry? Sharon Cunningham, CEO and Founder of Shorla Oncology shares invaluable insights on successful partnerships and collaborations. "Spending time really understanding if the potential partner shares your values as a company and ensuring that there's chemistry there from the beginning because otherwise, it's not going to work." That's where EVERSANA COMPLETE Commercialization shines! We not only bring expertise and industry knowledge but also prioritize the chemistry and alignment of values with our partners. Learn more: https://ow.ly/cGxh50QFks2 #CommercializationSuccess #COMPLETECommercialization #EVERSANAPartnership

The dynamics of the Presbyopia market is anticipated to change in the coming years owing to the expected launch of emerging therapies by major players such as Allergan (AbbVie), Eyenovia, Inc., Orasis Pharmaceuticals, Novartis, Ocuphire Pharma, Visus Therapeutics, Inc., and others during the forecasted period 2019-2032. Click here to know more about presbyopia market @ https://lnkd.in/djf_P4Ty

Timothy O’Shea, MS, PharmD, discusses the role of evidence-based recommendations around biosimilars and unbranded biologics for increasing patient care, plus how payers and providers evaluate biosimilars through clinical data across multiple indications. Watch here: https://bit.ly/48OFbz5 Timothy O'Shea

US companies are leading the race for next-generation therapeutics (NGT) championship. However, Europe is catching up. In the infographic, we depicted a pipeline analysis of the biggest pharmaceutical companies in the world. R&D intensity is the R&D expenditure as share of the total revenue. The bubble size represents the NGTs in relation to all entities in the pipeline. Find out more about the approach for mastering next-generation therapeutics in the Porsche Consulting Strategy Paper “Pharma’s transformation towards next-generation therapeutics”: https://lnkd.in/eeUTebZq #Pharma #NGT #NextGenerationTherapeutics #CellAndGeneTherapy #advancedtherapymedicinalproducts

Roche Makes Resounding Entry into Obesity Market! 💼💡 Roche, a global pharmaceutical giant, announces a resounding entry into the obesity market with a strategic move—acquiring Carmot Therapeutics, Inc. for a whopping upfront investment of $2.7 billion. Carmot, a biotech company, possesses a promising arsenal of injectable dual GLP-1/GIP receptor agonists and an oral GLP-1 drug currently advancing through clinical development. 💰 This strategic move by Roche involves a buyout offer to Carmot, originally poised for an initial public offering (IPO). The deal not only secures a significant upfront payment but also includes potential milestone payments of up to $400 million. #roche #CarmotTherapeutics #obesitytreatment #PharmaceuticalNews

In-Vitro Diagnostic Collaboration and Licensing Agreements Analysis Report 2023 with a Directory of Deals Signed by the World's Leading Biopharma Companies: DUBLIN, Nov. 22, 2023 /PRNewswire/ -- The "In Vitro Diagnostic Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering. In Vitro Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

Ulcerative Colitis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Eli Lilly, AbbVie, Pfizer, Arena Pharma, Janssen: Delveinsight Business Research LLP As per DelveInsight’s assessment, globally, about 110+ key pharma and biotech companies are working on 110+ pipeline drugs in the Ulcerative Colitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and … Continue reading → #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech